

**LIST OF TABLES:**

Table No.	Title of Table	Page No.
2.1	Standard Adjuvant Chemotherapy Regimens.	16
2.2	Examples of clinical-stage nanomedicines for cancer therapy.	20
2.3	In vivo studies of nanoparticle-mediated combination therapies for cancer treatment in mouse tumour models.	28
2.4	Inorganic nanoparticles and nanocomposite materials for controlled and targeted drug delivery and imaging purposes	34
2.5	Different types of mesoporous silica, type of used surfactant, crystallographic structure.	43
2.6	Comparison of the different silica sources available for the synthesis of silica-based mesoporous materials.	46
2.7	Active targeting ligands conjugated to mesoporous silica nanoparticles-based nanosystems that permit their specific recognition.	52
2.8	The pH-responsive nanosystems based on MSNs.	57
2.9	Redox-responsive nanosystems based on MSNs.	60
2.10	Enzyme-responsive nanosystems based on MSNs.	62
2.11	Thermo-responsive nanosystems based on MSNs.	63
2.12	Magnetic-responsive nanosystems based on MSNs.	64
2.13	Ultrasound (US)-responsive nanosystems based on MSNs.	65
2.14	Light-responsive nanosystems based on MSNs.	66

2.15	Multi stimuli responsive nanosystems based on MSNs.	68
3.1	Calibration curve of DOX in PBS (pH 7.4) by UV-Visible spectrophotometer.	101
3.2	Calibration curve of DOX in PBS (pH 7.4) by fluorescence spectroscopy.	104
3.3	Calibration curve of DOX in phosphate buffer (pH 5.5) by fluorescence spectroscopy.	106
3.4	Interference study data of different compounds by fluorescence spectroscopy.	107
3.5	Calibration curve of CuCl <sub>2</sub> in DDW by Atomic Absorption Spectroscopy.	109
3.6	Calibration curve of ZnCl <sub>2</sub> in DDW by Atomic Absorption Spectroscopy.	110
3.7	Calibration curve of APTES in methanol by UV-Visible spectrophotometer.	112
3.8	Calibration curve of Folic acid in 0.1N NaOH by UV-Visible spectrophotometer.	114
3.9	Calibration curve of silicic acid in PBS (pH 7.4) by UV Visible spectroscopy.	117
3.10	Calibration curve of silicic acid in urine by UV Visible spectroscopy.	118
4.1	List of Chemicals.	122
4.2	List of Equipments.	123
4.3	Comparison of synthetic parameters of MCM-41 and SBA-16 type of MSNs.	124
4.4	Synthesis of MCM-41 type of MSNs:	125
4.5	Synthesis of SBA-16 type of MSNs.	126
4.6	Synthesis of MO-MSNs.	127
4.7	Physicochemical Characterizations of MCM-41 type of MSNs.	136
4.8	Physicochemical Characterizations of SBA-16 type of MSNs.	137
4.9	Physicochemical Characterizations of MO-MSNs.	138

4.10	Particle size analysis and zeta potential of synthesized MSNs.	139
4.11	Determination of metal content in different MO-MSNs by AAS.	142
4.12	The BET surface area, pore size and pore volume of different MSNs.	144
4.13	FEG-SEM-EDS: elemental composition of MSNs and CuO-MSNs.	152
4.14	Comparison of MSNs synthesized using silicate with that of synthesized using alkoxide.	154
4.15	Comparison of batch F2 with MCM-41 type of MSNs available in market.	155
5.1	Hematological parameters of mice given single dose of MSNs (Acute toxicity)	169
5.2	Hematological parameters of mice given treated with CuO-MSNs for 14 days (Acute toxicity).	171
5.3	Hematological parameters of mice treated with MSNs for 1 days (Sub-acute toxicity).	175
5.4	Biochemical parameters of mice treated with MSNs for 15 days (Sub-acute toxicity).	177
5.5	Hematological parameters of mice treated with CuO-MSNs for 14 days (Sub-acute toxicity).	179
5.6	Biochemical parameters of mice treated with CuO-MSNs for 14 days (Sub-acute toxicity).	181
5.7	Hematological parameters of mice treated with MSNs and CuO-MSNs for 60 days (Chronic toxicity).	186
5.8	Biochemical parameters of mice treated with MSNs and CuO-MSNs for 60 days (Chronic toxicity).	187
6.1	List of chemicals used in the present work.	201
6.2	List of equipments used in the present work.	202
6.3	Amount of amino groups measured by performing ninhydrin test after each	214

	modification.	
6.4	DOX loading in differently functionalized MSNs.	215
7.1	List of Chemicals.	229
7.2	List of Instruments.	230
8.1	List of Chemicals.	252
8.2	List of Instruments.	253
8.3	Animal groups for in vivo anticancer study.	256
8.4	Hematological parameters of control group mice.	266
8.5	Hematological parameters of treatment group mice.	267